|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1523 News |
|
| «12...1314151617181920212223...3031» |
- ||||| New P2 trial: A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model (clinicaltrials.gov) - Nov 7, 2013
P2, N=101, Active, not recruiting, Sponsor: Genentech
- ||| Trial initiation date: Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older (clinicaltrials.gov) - Nov 6, 2013
P2, N=367, Active, not recruiting, Sponsor: GlaxoSmithKline
Initiation date: Feb 2013 --> Sep 2013
- Trial initiation date: Use of Probiotics to Prevent Influenza (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=1440, Recruiting, Sponsor: McMaster University
Initiation date: Feb 2013 --> Sep 2013 Initiation date: Jan 2013 --> Jul 2013
- Clinical: How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=15000, Recruiting, Sponsor: NorthShore University HealthSystem
- |||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Enrollment open: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Nov 6, 2013
P3, N=688, Enrolling by invitation, Sponsor: Sanofi Pasteur, a Sanofi Company
Initiation date: Jan 2013 --> Jul 2013 Not yet recruiting --> Enrolling by invitation
- Enrollment open: Use of Probiotics to Prevent Influenza (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=1440, Recruiting, Sponsor: McMaster University
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- Enrollment closed: AIMHi: Testing the Use of Prompts to Increase Adolescent Immunization Rates (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=7040, Active, not recruiting, Sponsor: University of Rochester
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- |||||| Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring
Enrollment open: Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. (clinicaltrials.gov) - Nov 6, 2013
P3, N=14832, Recruiting, Sponsor: Novartis Vaccines
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Fluzone (influenza vaccine) / Sanofi
New P4 trial: Immune and Hormone Response to Influenza Vaccine (clinicaltrials.gov) - Nov 5, 2013
P4, N=40, Active, not recruiting, Sponsor: Johns Hopkins Bloomberg School of Public Health
- Trial completion: Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study (clinicaltrials.gov) - Nov 5, 2013
P=N/A, N=20, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| MenHibrix (GSK 792014) / GSK
New P3 trial: Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix (clinicaltrials.gov) - Nov 5, 2013
P3, N=600, Recruiting, Sponsor: GlaxoSmithKline
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion: Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route (clinicaltrials.gov) - Nov 4, 2013
P1, N=40, Completed, Sponsor: International Vaccine Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial initiation date: A Randomized Trial of Vitamin D to Reduce Respiratory Infection (clinicaltrials.gov) - Nov 3, 2013
P=N/A, N=300, Active, not recruiting, Sponsor: McMaster University
Active, not recruiting --> Completed Initiation date: Nov 2012 --> Aug 2013
- Enrollment closed: A Randomized Trial of Vitamin D to Reduce Respiratory Infection (clinicaltrials.gov) - Nov 3, 2013
P=N/A, N=300, Active, not recruiting, Sponsor: McMaster University
Initiation date: Nov 2012 --> Aug 2013 Not yet recruiting --> Active, not recruiting
- Enrollment change: The Effect of Supplementation With Two Different Doses of Vitamin D on Bone Mineral Density, Vitamin D Levels and Hand Grip Strength in Children With Diabetes Mellitus Type 1 (clinicaltrials.gov) - Nov 2, 2013
P4, N=60, Completed, Sponsor: Medical University of Warsaw
Not yet recruiting --> Active, not recruiting N=100 --> 60
- Trial completion: The Effect of Supplementation With Two Different Doses of Vitamin D on Bone Mineral Density, Vitamin D Levels and Hand Grip Strength in Children With Diabetes Mellitus Type 1 (clinicaltrials.gov) - Nov 2, 2013
P4, N=60, Completed, Sponsor: Medical University of Warsaw
N=100 --> 60 Not yet recruiting --> Completed
- ||||| FluLaval Quadrivalent (influenza vaccine) / GSK
New P2 trial: Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age (clinicaltrials.gov) - Oct 31, 2013
P2, N=316, Active, not recruiting, Sponsor: GlaxoSmithKline
- ||| Enrollment closed: Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older (clinicaltrials.gov) - Oct 30, 2013
P2, N=367, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- New P1 trial: Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People (clinicaltrials.gov) - Oct 27, 2013
P1, N=200, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- tamoxifen / Generic mfg.
Enrollment closed: LOGRIBMET: Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer (clinicaltrials.gov) - Oct 27, 2013
P=N/A, N=115, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed: H7N9 Mix and Match With MF59 in Healthy Adults (clinicaltrials.gov) - Oct 23, 2013
P2, N=700, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations (clinicaltrials.gov) - Oct 23, 2013
P2, N=211, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion: A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine (clinicaltrials.gov) - Oct 22, 2013
P1, N=36, Completed, Sponsor: Medigen Biotechnology Corporation
Active, not recruiting --> Completed Recruiting --> Completed
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion: Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine (clinicaltrials.gov) - Oct 22, 2013
P1, N=30, Completed, Sponsor: Patricia L. Hibberd
Recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| New P3 trial: Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan (clinicaltrials.gov) - Oct 21, 2013
P3, N=100, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- FLUAD (trivalent inactivated influenza vaccine) / CSL Behring, Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion: Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa (clinicaltrials.gov) - Oct 17, 2013
P2, N=296, Completed, Sponsor: Program for Appropriate Technology in Health
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring
New P3 trial: Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. (clinicaltrials.gov) - Oct 15, 2013
P3, N=14832, Recruiting, Sponsor: Novartis Vaccines
- ||| Trial completion: Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents (clinicaltrials.gov) - Oct 14, 2013
P1, N=75, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
Trial completion: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) (clinicaltrials.gov) - Oct 13, 2013
P3, N=1315, Completed, Sponsor: Sanofi Pasteur MSD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Flublok (influenza vaccine) / Sanofi, Ildong, Shionogi
New P3 trial: A Study to Evaluate Intramuscular ASP7374 (clinicaltrials.gov) - Oct 10, 2013
P3, N=55, Completed, Sponsor: Astellas Pharma Inc
- |||||||||| Flublok (influenza vaccine) / Sanofi, Ildong, Shionogi
New P3 trial, Preclinical: Study of ASP7374, Cell-culture-derived Influenza Vaccine (clinicaltrials.gov) - Oct 10, 2013
P3, N=900, Completed, Sponsor: Astellas Pharma Inc
- ||||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial completion: Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines (clinicaltrials.gov) - Oct 9, 2013
P3, N=582, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Flublok Quadrivalent (influenza vaccine) / Sanofi
New P3 trial: Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation) (clinicaltrials.gov) - Oct 8, 2013
P3, N=4100, Not yet recruiting, Sponsor: Protein Sciences Corporation
- ||||||| Flublok (influenza vaccine) / Sanofi, Ildong, Shionogi
Trial completion: Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age (clinicaltrials.gov) - Oct 7, 2013
P3, N=2639, Completed, Sponsor: Protein Sciences Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- oseltamivir / Generic mfg.
Enrollment change: A Study of the Pharmacology of Tamiflu in Pregnancy (clinicaltrials.gov) - Oct 7, 2013
P=N/A, N=63, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed N=100 --> 63
- oseltamivir / Generic mfg.
Trial completion: A Study of the Pharmacology of Tamiflu in Pregnancy (clinicaltrials.gov) - Oct 7, 2013
P=N/A, N=63, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N=100 --> 63 Recruiting --> Completed
- ||||||| Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion: Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years (clinicaltrials.gov) - Oct 6, 2013
P3, N=3360, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed Active, not recruiting --> Completed
- || Enrollment closed: Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age (clinicaltrials.gov) - Oct 3, 2013
P1, N=427, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Fluarix Quadrivalent (influenza vaccine) / GSK
New P3 trial: Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older (clinicaltrials.gov) - Sep 29, 2013
P3, N=828, Active, not recruiting, Sponsor: GlaxoSmithKline
- ||| Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Enrollment closed: Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults (clinicaltrials.gov) - Sep 24, 2013
P4, N=208, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Naphcon-A (naphazoline HCl) / Novartis, Alervil (pheniramine maleate) / Incepta
Enrollment closed: Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal (clinicaltrials.gov) - Sep 23, 2013
P3, N=212, Active, not recruiting, Sponsor: EMS
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- ||||| New P2 trial: Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older (clinicaltrials.gov) - Sep 22, 2013
P2, N=367, Active, not recruiting, Sponsor: GlaxoSmithKline
- ||||||| Fluvirin (inactivated influenza virus vaccine) / CSL Behring
Trial completion: Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above (clinicaltrials.gov) - Sep 22, 2013
P3, N=125, Completed, Sponsor: Novartis Vaccines
Not yet recruiting --> Active, not recruiting Recruiting --> Completed
- ||||||| Trial completion: Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above (clinicaltrials.gov) - Sep 22, 2013
P3, N=126, Completed, Sponsor: Novartis Vaccines
Recruiting --> Completed Recruiting --> Completed
- Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion: Inactivated Influenza Vaccine Effectiveness in Tropical Africa (clinicaltrials.gov) - Sep 18, 2013
P4, N=10000, Completed, Sponsor: Program for Appropriate Technology in Health
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine (clinicaltrials.gov) - Sep 18, 2013
P1, N=48, Completed, Sponsor: Program for Appropriate Technology in Health
Active, not recruiting --> Completed Active, not recruiting --> Completed
- paracetamol / Generic mfg.
New P4 trial: Clinical Immunization Safety Assessment (CISA) Project: Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After IIV (clinicaltrials.gov) - Sep 17, 2013
P4, N=41, Active, not recruiting, Sponsor: Duke University
- ||||| Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P4 trial: Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults (clinicaltrials.gov) - Sep 17, 2013
P4, N=208, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- ||||| Fluzone Quadrivalent (influenza vaccine) / Sanofi
New P4 trial: Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine (clinicaltrials.gov) - Sep 17, 2013
P4, N=60, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- | Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
New P2 trial, Adverse events: IVVE:Pilot: Influenza Vaccine To Prevent Adverse Vascular Events:Pilot (clinicaltrials.gov) - Sep 16, 2013
P2, N=600, Not yet recruiting, Sponsor: McMaster University